Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States

Benzer Materyaller

• Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
  Yazar:: Jorge J Castillo, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-02-01)
• Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia
  Yazar:: Silvia Robuffo, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-01-01)
• Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
  Yazar:: Javier Muñoz, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-10-01)
• Pathophysiology of Waldenström’s macroglobulinemia
  Yazar:: Marvin J. Stone, ve diğerleri
  Baskı/Yayın Bilgisi: (2010-03-01)
• P110 | ZANUBRUTINIB IN WALDENSTROM MACROGLOBULINEMIA. REPORT ON THE EXPERIENCE OF THE CAMPANIA GROUP ON CLL/WM: THE DIAGNOSTIC AND INTEGRATED DIRECTION FOR OPTIMIZED CAMPANIA NETWORKING IN WALDENSTROM DISEASE (DIDONE) PROJECT.
  Yazar:: G. D'arena, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-09-01)